Gongwin Biopharm Holdings Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	1,005	893.47	273.59	671.51	454.12	707.23
Short-Term Investments	188.21	848.99	668.66	434.1	372.2	297.09
Trading Asset Securities	447.77	466.79	-	-	-	34.41
Cash & Short-Term Investments	1,641	2,209	942.25	1,106	826.33	1,039
Cash Growth	-28.38%	134.47%	-14.78%	33.80%	-20.45%	60.78%
Accounts Receivable	13.78	14.17	10.58	-	-	-
Other Receivables	10.05	12.31	4.52	4.25	0.06	0.21
Receivables	23.83	26.48	15.1	4.25	0.06	0.21
Inventory	2.65	3.59	11.93	0.21	-	-
Prepaid Expenses	16.01	12.89	11.36	11.11	-	-
Other Current Assets	167.81	180.62	138.42	215.88	93.74	21.34
Total Current Assets	1,851	2,433	1,119	1,337	920.12	1,060
Property, Plant & Equipment	321.23	330.89	118.32	245.05	246.76	136.97
Long-Term Investments	476.66	497.81	156.61	32.35	3.88	5.34
Other Intangible Assets	0.64	0.37	0.19	-	-	0.01
Other Long-Term Assets	119.82	120.3	121.17	7.47	1.12	1.42
Total Assets	2,770	3,382	1,515	1,622	1,172	1,204
Accounts Payable	0.16	0.21	0.29	-	-	-
Accrued Expenses	45.24	28.51	26.37	32.63	21.97	19.03
Short-Term Debt	101.34	110.63	75.02	134.55	113.06	29.28
Current Portion of Leases	3.01	3.21	2.12	5.01	1.99	4.7
Current Income Taxes Payable	15.12	15.7	15.13	15.44	15.2	-
Other Current Liabilities	4.75	23.9	7.44	3.62	2.54	2.66
Total Current Liabilities	169.62	182.16	126.36	191.26	154.75	55.66
Long-Term Leases	9.72	12.91	0.03	2.18	0.1	2.11
Long-Term Unearned Revenue	45.5	45.01	45.08	42.03	29.57	27.97
Other Long-Term Liabilities	35.31	41.76	32.06	13.24	0	-
Total Liabilities	260.15	281.84	203.53	248.7	184.43	85.75
Common Stock	1,275	1,275	1,133	1,131	1,099	1,093
Additional Paid-In Capital	3,500	3,500	1,644	1,634	1,061	1,045
Retained Earnings	-1,598	-1,529	-1,441	-1,349	-1,094	-972.88
Treasury Stock	-532.98	-166.61	-	-	-	-
Comprehensive Income & Other	-124.64	27.14	-21.35	-24.77	-95.34	-71.36
Total Common Equity	2,519	3,107	1,315	1,392	970.72	1,093
Minority Interest	-9.07	-6.2	-3.68	-18.58	16.74	25.21
Shareholders' Equity	2,510	3,100	1,312	1,373	987.45	1,118
Total Liabilities & Equity	2,770	3,382	1,515	1,622	1,172	1,204
Total Debt	114.08	126.75	77.17	141.74	115.14	36.09
Net Cash (Debt)	1,527	2,082	865.08	963.87	711.19	1,003
Net Cash Growth	-29.77%	140.73%	-10.25%	35.53%	-29.07%	61.07%
Net Cash Per Share	12.27	17.24	7.64	8.67	6.49	9.60
Filing Date Shares Outstanding	122.62	126.06	113.34	113.09	109.92	109.27
Total Common Shares Outstanding	122.62	126.06	113.34	113.09	109.92	109.27
Working Capital	1,682	2,251	992.7	1,146	765.37	1,005
Book Value Per Share	20.54	24.64	11.61	12.31	8.83	10.00
Tangible Book Value	2,518	3,106	1,315	1,392	970.72	1,093
Tangible Book Value Per Share	20.54	24.64	11.61	12.31	8.83	10.00
Land	228.65	228.65	49.69	155	155	49.69
Buildings	74.88	75.29	52.95	69.59	69.23	53.22
Machinery	72.5	73.96	63.43	56.76	54.91	54.13
Construction In Progress	-	-	-	-	0.54	-
Leasehold Improvements	-	-	3.75	3.75	3.75	3.75

Source: S&P Global Market Intelligence. Standard template. Financial Sources.